No Data
Haier Biotech: Haier Biotech 2024 Annual Performance Report Announcement
Haier Biotech 2024 Annual Results Report Announcement
Qingdao Haier Biomedical Co., Ltd. (688139.SH): In 2024, the net income is 0.367 billion yuan, a decrease of 9.71% year-on-year.
On February 27, Gelonghui reported that Qingdao Haier Biomedical Co., Ltd. (688139.SH) published its performance briefing for 2024, showing a revenue of 2,283.8329 million yuan, signaling a return to positive growth. By actively responding to external environmental challenges, the Business development during the reporting period showed a positive trend. Compared to the previous year, following a return to positive growth in revenue during the third quarter, the growth rate in the fourth quarter further increased to 10.40%, with both domestic and overseas markets, as well as the storage and non-storage industries, all achieving growth in the fourth quarter. On a quarter-on-quarter basis, despite some Orders being delivered across periods in the fourth quarter, the growth in Orders remained consistent compared to the previous quarter.
Qingdao Haier Biomedical Co., Ltd. (688139.SH): The controlling shareholders and acting in concert together increased their shareholding by 1.06%.
Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced that the company's actual controller, Haier Group Corporation, has a concerted party, Qingdao...
Qingdao Haier Biomedical Co., Ltd. (688139.SH): The company's vaccine appointment and vaccination system has been integrated with DeepSeek.
On February 25, Gelonghui reported that Qingdao Haier Biomedical Co., Ltd. (688139.SH) stated on an interactive platform that in the scenario of smart public health, the company's vaccine appointment and vaccination system has integrated with DeepSeek, which quickly understands various user expressions based on natural language processing technology, accurately answers user queries, and recommends the optimal vaccination plan according to personalized needs. In the scenario of smart medication use within hospitals, the company relies on the deep learning capabilities of the DeepSeek-R1 large model to build AI-driven products such as dynamic inventory management systems, pre-review large models for prescriptions, and personalized medication models, effectively reducing pharmacy operation costs.
We Think Qingdao Haier BiomedicalLtd (SHSE:688139) Can Stay On Top Of Its Debt
Market Still Lacking Some Conviction On Qingdao Haier Biomedical Co.,Ltd (SHSE:688139)
